NasdaqGS:ZYMEBiotechs
Does Zymeworks (ZYME) Pan-RAS ADC Push Reveal a Durable Edge in Targeted Oncology?
Zymeworks announced that its wholly owned R&D portfolio, including clinical-stage ADC ZW191 and several novel pan-RAS inhibitor ADCs, was featured in one oral and six poster presentations at the 2026 AACR Annual Meeting, showcasing new clinical and preclinical oncology data across multiple difficult-to-treat cancers.
An interesting angle for investors is how Zymeworks is using proprietary payloads and targeted ADC designs to address RAS-mutated tumors, an area where traditional...